JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

166.57 -2.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

164.44

Máximo

169.65

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+18.29% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

508M

8.4B

Abertura anterior

169.38

Fecho anterior

166.57

Sentimento de Notícias

By Acuity

19%

81%

48 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de abr. de 2026, 23:33 UTC

Ações em Alta

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 de abr. de 2026, 23:24 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 de abr. de 2026, 22:46 UTC

Ganhos

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 de abr. de 2026, 22:37 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 de abr. de 2026, 22:15 UTC

Ganhos
Notícias Principais

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 de abr. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 de abr. de 2026, 23:19 UTC

Conversa de Mercado
Ganhos

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 de abr. de 2026, 23:09 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 de abr. de 2026, 23:03 UTC

Conversa de Mercado

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 de abr. de 2026, 22:51 UTC

Ganhos

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 de abr. de 2026, 22:40 UTC

Conversa de Mercado
Notícias Principais

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 de abr. de 2026, 22:32 UTC

Ganhos

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 de abr. de 2026, 22:22 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 de abr. de 2026, 22:17 UTC

Conversa de Mercado

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 de abr. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

18.29% parte superior

Previsão para 12 meses

Média 197.3 USD  18.29%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

48 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat